6th Sub. S.B. 89 CANNABIS-BASED MEDICINE AMENDMENTS

HOUSE FLOOR AMENDMENTS

AMENDMENT 2 MARCH 9, 2016 8:22 PM

Representative **Robert M. Spendlove** proposes the following amendments:

- 1. Page 20, Lines 612 through 613:
 - (d) a trans-dermal preparation; {-or-}
 - (e) a sub-lingual preparation (-); or
 - (f) for cannabis-based medicine that is expanded CBM as defined in Section 58-37-3.6, a liquid intended for use in a device that generates a vapor by warming the liquid with a heating element.
- 2. Page 38, Lines 1170 through 1171:
 - 1170 (a) "Cannabis-based medicine specialist" means a physician with a cannabis-based
 - medicine specialist certification issued by the division under Subsection (2)
- 3. Page 38, Line 1174:
 - (c) "Expanded CBM" means the same as that term is defined in Section 58-37-3.6.
 - 1174 (2) The division may issue a cannabis-based medicine certification to a physician who:
- 4. Page 39, Line 1179:
- 1179 Chapter 3, Utah Administrative Rulemaking Act.
 - (3) The division may issue an expanded CBM certification to a physician who completes training in cannabis-based medicine developed by the division in coordination with the department and required by the division by rule made in accordance with Title 63G Chapter 3, Utah Administrative Rulemaking Act.
- 5. Page 39, Line 1180:
 - 1180 {-(3)} A cannabis-based medicine specialist may recommend treatment with
- 6. Page 39, Line 1187:
 - 1187 { (4) } (5) A cannabis-based medicine specialist may recommend treatment with cannabis
- 7. Page 39, Lines 1195 through 1196:
 - (6) A physician with an expanded CBM certification issued by the division under Subsection (3) may recommend expanded CBM to a patient if:
 - (a) (i) the physician is board certified in hematology or oncology; and

- (ii) the patient is being actively treated for a diagnosed malignancy or is being provided palliative care for an incurable malignancy;
- (b) (i) the physician is a hospice director who, after a face-to-face evaluation with the patient, determines that the patient has six months or less to live; and
 - (ii) the patient is being actively treated by a licensed hospice care provider; or
 - (c) (i) the physician is an infectious disease specialist; and
- (ii) the patient is diagnosed with HIV- or AIDS-associated anorexia and wasting syndrome.
- 1195 {(5)} (7) A patient to whom a physician recommends cannabis-based medicine under 1196 Subsection {(3) or } (4) ,(5), or (6) is eligible for a medical cannabis card under this section.
 - <u>(8) (a) An individual with a medical cannabis card may not purchase expanded CBM at a CBM dispensary unless the individual's physician recommends expanded CBM to the individual in compliance with this section.</u>
 - (b) A physician may not recommend expanded CBM to an individual except in compliance with this section.
 - (9) A physician with an expanded CBM certification who recommends expanded CBM to a patient under Subsection (6) may recommend that the patient use expanded CBM in the form of a liquid intended for use in a device that generates a vapor by warming the liquid with a heating element.
- 8. Page 45, Lines 1373 through 1377:
 - 1373 (a) " {Cannabis-based | Standard cannabis-based | medicine" | or "standard |
 CBM" | means a product intended for human ingestion that:
 - (i) contains an extract or concentrate that is obtained from cannabis;
 - 1375 (ii) is prepared in a medicinal dosage form as required by Section 4-42-602; and
 - (iii) contains at least one unit of cannabidiol for every one unit of
 - 1377 tetrahydrocannabinol.
- 9. Page 45, Line 1379:
 - (c) "Cannabis-based medicine" means expanded CBM or standard CBM.
 - {(d) _"Drug paraphernalia" means the same as that term is defined in Section 58-37a-3.
 - (e) "Expanded cannabis-based medicine" or expanded CBM" means a product intended for human ingestion that:
 - (i) contains an extract or concentrate that is obtained from cannabis; and
 - (ii) is prepared in a medicinal dosage form as required by Section 4-42-602.

1379